{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:25:43Z","timestamp":1777861543676,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000171","name":"Division of Human Resource Development","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16\\u20132017\\u201300009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16\\u20132017\\u201300009"]}],"id":[{"id":"10.13039\/100000171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NKFI-PD-146373"],"award-info":[{"award-number":["NKFI-PD-146373"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NKFI-K-142799"],"award-info":[{"award-number":["NKFI-K-142799"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cell Biology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejcb.2024.151468","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:16:31Z","timestamp":1732036591000},"page":"151468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased mTOR activity and RICTOR copy number in small cell lung carcinoma progression"],"prefix":"10.1016","volume":"103","author":[{"given":"D\u00e1niel","family":"Sztankovics","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatime","family":"Szalai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorottya","family":"Moldvai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titanilla","family":"Dank\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mi","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"P\u00e1pay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Kho\u00f3r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Krencz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejcb.2024.151468_bib1","article-title":"Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment","volume":"73","author":"Alagheband","year":"2022","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ejcb.2024.151468_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3892\/etm.2011.291","article-title":"Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors","volume":"2","author":"Al\u00ec","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejcb.2024.151468_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1034292","article-title":"A molecular study of pediatric pilomyxoid and pilocytic astrocytomas: Genome-wide copy number screening, retrospective analysis of clinicopathological features and long-term clinical outcome","volume":"13","author":"AlShail","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib4","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","article-title":"Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","volume":"29","author":"Basu","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/annonc\/mdt535","article-title":"A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer","volume":"25","author":"Besse","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/2159-8290.CD-14-0971","article-title":"RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1\/2 inhibitors","volume":"5","author":"Cheng","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejcb.2024.151468_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 Studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cpt.2022.09.001","article-title":"PI3K\/AKT\/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer","volume":"1","author":"Deng","year":"2022","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.ejcb.2024.151468_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ejcb.2024.151468_bib10","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejcb.2024.151468_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/genes11091045","article-title":"Regulation of mTORC2 signaling","volume":"11","author":"Fu","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ejcb.2024.151468_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrc.2017.106","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejcb.2024.151468_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/ijms22010030","article-title":"Pharmacological inhibition of mTORC2 reduces migration and metastasis in melanoma","volume":"22","author":"Guenzle","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejcb.2024.151468_bib15","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ebiom.2015.09.031","article-title":"Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the international lung cancer consortium","volume":"2","author":"Huang","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejcb.2024.151468_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells","volume":"16","author":"Kahn","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jtho.2020.05.026","article-title":"Role of mTOR As an essential kinase in SCLC","volume":"15","author":"Kern","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib18","first-page":"1","article-title":"Recent progress in mapping the emerging landscape of the small-cell lung cancer genome","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejcb.2024.151468_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/annonc\/mdw669","article-title":"Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1\/2 inhibition","volume":"28","author":"Kim","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib20","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013122","article-title":"Mechanisms of small cell lung cancer metastasis","volume":"13","author":"Ko","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejcb.2024.151468_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.humpath.2019.08.018","article-title":"Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma","volume":"93","author":"Krencz","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejcb.2024.151468_bib22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10555-021-10012-4","article-title":"Progression and metastasis of small cell lung carcinoma: the role of the PI3K\/Akt\/mTOR pathway and metabolic alterations","volume":"40","author":"Krencz","year":"2021","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.ejcb.2024.151468_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejcb.2024.151468_bib24","first-page":"2987","article-title":"Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer","volume":"8","author":"Lee","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejcb.2024.151468_bib25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejcb.2024.151468_bib26","doi-asserted-by":"crossref","first-page":"109596","DOI":"10.18632\/oncotarget.22741","article-title":"TRIB2 contributes to cisplatin resistance in small cell lung cancer","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcb.2024.151468_bib27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ijc.28126","article-title":"Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2","volume":"133","author":"Lin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejcb.2024.151468_bib28","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejcb.2024.151468_bib29","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejcb.2024.151468_bib30","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.biopha.2018.06.083","article-title":"17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting HSP90 gene expression","volume":"105","author":"Mellatyar","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejcb.2024.151468_bib31","article-title":"Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells","volume":"66","author":"Mogheri","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ejcb.2024.151468_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: Role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejcb.2024.151468_bib33","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/cncr.33048","article-title":"Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy","volume":"126","author":"Park","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejcb.2024.151468_bib34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib35","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejcb.2024.151468_bib36","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejcb.2024.151468_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00401-011-0933-9","article-title":"Brain metastases: pathobiology and emerging targeted therapies","volume":"123","author":"Preusser","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejcb.2024.151468_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jclinpath-2014-202447","article-title":"Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer","volume":"67","author":"Ross","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejcb.2024.151468_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejcb.2024.151468_bib42","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.18632\/oncotarget.13362","article-title":"RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR","volume":"8","author":"Sakre","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcb.2024.151468_bib43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejcb.2024.151468_bib44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejcb.2024.151468_bib45","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.neo.2018.10.001","article-title":"Inhibition of mTORC2\/RICTOR impairs melanoma hepatic metastasis","volume":"20","author":"Schmidt","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejcb.2024.151468_bib46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10555-021-10006-2","article-title":"The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues","volume":"40","author":"Sebesty\u00e9n","year":"2021","journal-title":"Cancer Metastas\u00a0Rev."},{"key":"10.1016\/j.ejcb.2024.151468_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejcb.2024.151468_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.canlet.2009.03.038","article-title":"Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer","volume":"283","author":"Shibata","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejcb.2024.151468_bib49","first-page":"488","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J. Pathol","volume":"241","author":"Simbolo","year":"2017"},{"key":"10.1016\/j.ejcb.2024.151468_bib50","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","article-title":"Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation","volume":"13","author":"Sivakumar","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejcb.2024.151468_bib51","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjc.2013.467","article-title":"A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer","volume":"109","author":"Sun","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejcb.2024.151468_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/cancers16030543","article-title":"Rictor-a mediator of progression and metastasis in lung cancer","volume":"16","author":"Szalai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejcb.2024.151468_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1610996","article-title":"3D bioprinting and the revolution in experimental cancer model systems-a review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures","volume":"29","author":"Sztankovics","year":"2023","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejcb.2024.151468_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46927-x","article-title":"Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing","volume":"13","author":"Sztankovics","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejcb.2024.151468_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2024.1611643","article-title":"mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies","volume":"30","author":"Sztankovics","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejcb.2024.151468_bib56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mtor inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejcb.2024.151468_bib57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1126\/science.aaz4016","article-title":"Double trouble for cancer gene","volume":"366","author":"Toker","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejcb.2024.151468_bib58","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol. 21, 645-654 (2020). Errat-.-. : Lancet Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib59","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/JTO.0000000000000250","article-title":"Therapeutic priority of the PI3K\/AKT\/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis","volume":"9","author":"Umemura","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejcb.2024.151468_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2017.06.002","article-title":"Treatment advances in small cell lung cancer (SCLC)","volume":"180","author":"Waqar","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejcb.2024.151468_bib61","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-17-2388","article-title":"Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival","volume":"78","author":"Werfel","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcb.2024.151468_bib62","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1158\/0008-5472.CAN-10-0207","article-title":"mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcb.2024.151468_bib63","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2011.02.014","article-title":"Activation of mTORC2 by association with the ribosome","volume":"144","author":"Zinzalla","year":"2011","journal-title":"Cell"}],"container-title":["European Journal of Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171933524000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171933524000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:25:02Z","timestamp":1777523102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171933524000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0171933524000852"],"URL":"https:\/\/doi.org\/10.1016\/j.ejcb.2024.151468","relation":{},"ISSN":["0171-9335"],"issn-type":[{"value":"0171-9335","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased mTOR activity and RICTOR copy number in small cell lung carcinoma progression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejcb.2024.151468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"151468"}}